FDA Gives Green Signal To Compass Therapeutics' Mid-Stage Biliary Tract Cancer Trial In US


The FDA has signed off Compass Therapeutics Inc's CMPX IND application for CTX-009 to initiate a global Phase 2 clinical trial for CTX-009 for advanced Biliary Tract Cancers (BTC) in the U.S. and South Korea. 

  • The Company plans to include the existing Phase 2 in South Korea in this global study, allowing it to expand the ongoing study of CTX-009 under this IND. 
  • CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A).
  • The Phase 2a trial in South Korea is testing CTX-009 combined with paclitaxel in BTC patients. 
  • The Company said that five partial responses have already been observed among the first 17 patients evaluated, leading to a preliminary overall response rate (ORR) of 29%.
  • All patients evaluated have had stable disease or better, with a decline in tumor burden observed in 16 of the 17 patients leading to a Clinical Benefit Rate of 100%. 
  • Price Action: CMPX shares are down 1.06% at $2.80 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!